Cha University
Clinical trials sponsored by Cha University, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Scientists hunt for genetic signs to personalize bile duct cancer therapy Results expected Sep 2026 (estimated)
- Blood test may replace biopsies for bile duct cancer patients Results expected Dec 2026 (estimated)
- Suicide gene stem cells take aim at glioblastoma Results expected Dec 2026 (estimated)
- Blood test could replace needle biopsies for bile duct cancer patients Results expected Aug 2027 (estimated)
- Can an Anti-Inflammatory drug make liver cancer immunotherapy safer? Results expected Sep 2027 (estimated)
-
Can an Anti-Inflammatory drug make liver cancer immunotherapy safer?
Disease control Not yet recruitingThis phase II trial is testing whether adding tocilizumab, an anti-inflammatory drug, to a standard two-drug immunotherapy regimen can reduce severe immune-related side effects in people with advanced liver cancer. The study enrolls about 51 adults with hepatocellular carcinoma t…
Phase 2 • Sponsor: CHA University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Bile may hold the key to guiding targeted treatment for bile duct and gallbladder cancers
Diagnosis Not yet recruitingResearchers want to know whether leftover bile fluid can reveal genetic changes in tumors of people with advanced biliary tract cancer, such as bile duct or gallbladder cancer. Collecting tumor tissue for genetic testing can be difficult or risky in this cancer, so the study coll…
Sponsor: CHA University • Aim: Diagnosis
Last updated Sep 21, 2026 16:00 UTC